The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling
Open accessAbstract
Previous studies have demonstrated that intravitreal delivery of brain-derived neurotrophic factor (BDNF) by injection of recombinant protein or by gene therapy can alleviate retinal ganglion cell (RGC) loss after optic nerve injury. BDNF gene therapy can improve RGC survival in experimental models of glaucoma, the leading cause of irreversible blindness worldwide. However, the therapeutic efficacy of BDNF supplementation alone is time limited at least in part due to BDNF receptor downregulation. Tropomyosin-related receptor kinase-B (TrkB) downregulation has been reported in many neurological diseases including glaucoma, potentially limiting the effect of sustained or repeated BDNF delivery. Here, we characterize a novel adeno-associated virus (AAV) gene therapy (AAV2 TrkB-2A-mBDNF) that not only increases BDNF production but also improves long-term neuroprotective signaling by increasing expression of the BDNF receptor (TrkB) within the inner retina. This approach leads to significant and sustained elevation of survival signaling pathways ERK and AKT within RGCs over 6 months and avoids the receptor downregulation which we observe with treatment with AAV2 BDNF alone. We validate the neuroprotective efficacy of AAV2 TrkB-2A-mBDNF in a mouse model of optic nerve injury, where it outperforms conventional AAV2 BDNF or AAV2 TrkB therapy, before showing powerful proof of concept neuroprotection of RGCs and axons in a rat model of chronic intraocular pressure (IOP) elevation. We also show that there are no adverse effects of the vector on retinal structure or function as assessed by histology and electroretinography in young or aged animals. Further studies are underway to explore the potential of this vector as a candidate for progression into clinical studies to protect RGCs in patients with glaucoma and progressive visual loss despite conventional IOP-lowering treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuroprotective factors that support the survival of retinal cells, such as glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), basic fibroblast growth factor, and pigment epithelium-derived factor (PEDF) have shown promise in mouse models of retinal degeneration.67,103–105”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [105]
In the citing paper
“Supporting the promise of this method, AAV delivery of BDNF and its receptor105 or CNTF106 promoted survival and function of retinal ganglion cells in models of optic nerve crush or retinal ganglion cell degeneration in a model for experimental glaucoma, respectively.”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537
Regulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
Jonas, J. B., Aung, T., Bourne, R. R., Bron, A. M., Ritch, R., & Panda-Jonas, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31469-1 · Cited by 1,322
ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75NTRand Sortilin
Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., Kermani, P., Torkin, R., Chen, Z.-Y., Lee, F. S., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5123-04.2005 · Cited by 1,013
The molecular basis of retinal ganglion cell death in glaucoma
Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.002 · Cited by 971
Postsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and disease
Yoshii, A., & Constantine‐Paton, M. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20765 · Cited by 744
Mansour-Robaey, S., Clarke, D. B., Wang, Y. C., Bray, G. M., & Aguayo, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1632 · Cited by 731
Burgess, A., Vigneron, S., Brioudes, E., Labbé, J.-C., Lorca, T., & Castro, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914191107 · Cited by 680
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
Garway-Heath, D. F., Crabb, D. P., Bunce, C., Lascaratos, G., Amalfitano, F., Anand, N., Azuara-Blanco, A., Bourne, R. R., Broadway, D. C., Cunliffe, I. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62111-5 · Cited by 660
Self-citation
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Kompella, U. B., Hartman, R. R., & Patil, M. A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100901 · Cited by 129
Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment
Cvenkel, B., & Kolko, M. (2020) · Journal of Ophthalmology · doi:10.1155/2020/6138132 · Cited by 150
“*e neuroprotective efficacy was confirmed in an experimental animal model of glaucoma and optic nerve injury and was present over 6 months without vector-related adverse effects [133].”
Fudalej, E., Justyniarska, M., Kasarełło, K., Dziedziak, J., Szaflik, J. P., & Cudnoch‐Jędrzejewska, A. (2021) · Ophthalmic Research · doi:10.1159/000514441 · Cited by 112
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering
Tribble, J. R., Hui, F., Quintero, H., Hajji, S. E., Bell, K. C., Polo, A. D., & Williams, P. A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101193 · Cited by 136
Metadata
- Authors
- Osborne, A., Khatib, T. Z., Songra, L., Barber, A. C., Hall, K., Kong, G. Y. X., Widdowson, P. S., & Martin, K. R.
- Affiliations
- University of Cambridge (GB)
- The University of Melbourne (AU)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Corresponding author
- Martin, Keith R.
- Venue
- Cell Death & Disease
- Published
- 2018-09-26
- Volume
- 9
- Issue
- 10
- Pages
- 1007-1007
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC6158290
- OpenAlex
- W2894232396
- Cited by
- 175
- References
- 59
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 23 · 2023: 29 · 2022: 26 · 2021: 25 · 2020: 20 · 2019: 13
- FWCI
- 14.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- the Wellcome Trust (Pathfinder Award), the Midven Rainbow Seed Fund, Quethera Ltd, University of Cambridge Enterprise, the HB Allen Charitable Trust and the Cambridge Eye Trust
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- retinal ganglion cells, neuroprotection, glaucoma, brain-derived neurotrophic factor, TrkB receptor, adeno-associated virus gene therapy, AAV2, optic nerve injury, ERK signaling, Akt signaling, receptor down-regulation, inner retina, axon survival
- MeSH terms
- Neuroprotection, Dependovirus, Animals, Axons, Disease Models, Animal, Glaucoma, Humans, Intraocular Pressure, Male, Membrane Glycoproteins, Mice, Inbred C57BL, Retina, Retinal Ganglion Cells, Genetic Therapy, Signal Transduction, Down-Regulation, Rats, Sprague-Dawley, Brain-Derived Neurotrophic Factor, Optic Nerve Injuries, Receptor, trkB, Mice, Rats, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling. https://app.cochat.ai/papers/10.1038/s41419-018-1041-8
- The paper
- Osborne, A., Khatib, T. Z., Songra, L., Barber, A. C., Hall, K., Kong, G. Y. X., Widdowson, P. S., & Martin, K. R. (2018). Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling. Cell Death & Disease. https://doi.org/10.1038/s41419-018-1041-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.